[{"address1": "1 Caspian Point", "address2": "Caspian Way", "city": "Cardiff", "zip": "CF10 4DQ", "country": "United Kingdom", "phone": "44 29 2048 0180", "website": "https://www.biodexapharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. In addition, the company offers licensing for MTD 201 (Q-octreotide) and MTD211 (Q-brexpiprazole). The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.", "fullTimeEmployees": 21, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen A. Stamp", "age": 61, "title": "CEO, CFO, Company Secretary & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 316480, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dmitry  Zamoryakhin M.D.", "age": 43, "title": "Chief Scientific Officer & Chief Medical Officer", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 299344, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Daniel  Palmer MBA, Ph.D.", "title": "Vice President of Technology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Nicola  Tuckwell", "title": "VP & Head of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Fiona  Sharp", "title": "Group Financial Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.31, "open": 1.23, "dayLow": 1.16, "dayHigh": 1.6101, "regularMarketPreviousClose": 1.31, "regularMarketOpen": 1.23, "regularMarketDayLow": 1.16, "regularMarketDayHigh": 1.6101, "beta": 1.569, "volume": 1815248, "regularMarketVolume": 1815248, "averageVolume": 3390200, "averageVolume10days": 7582200, "averageDailyVolume10Day": 7582200, "bid": 1.42, "ask": 1.52, "bidSize": 100, "askSize": 100, "marketCap": 6621350, "fiftyTwoWeekLow": 0.67, "fiftyTwoWeekHigh": 20.8, "priceToSalesTrailing12Months": 17.378872, "fiftyDayAverage": 1.14828, "twoHundredDayAverage": 3.17931, "currency": "USD", "enterpriseValue": 2643030528, "floatShares": 1192631212, "sharesOutstanding": 4385000, "sharesShort": 189612, "sharesShortPriorMonth": 102627, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0432, "heldPercentInsiders": 0.09939, "heldPercentInstitutions": 0.18938999, "shortRatio": 0.04, "shortPercentOfFloat": 0.0432, "impliedSharesOutstanding": 4249510, "bookValue": 1.573, "priceToBook": 0.95994914, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -7079000, "trailingEps": -10.01, "lastSplitFactor": "1:80", "lastSplitDate": 1688515200, "enterpriseToRevenue": 6937.088, "enterpriseToEbitda": -409.265, "52WeekChange": -0.91381276, "SandP52WeekChange": 0.23099434, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "BDRX", "underlyingSymbol": "BDRX", "shortName": "Biodexa Pharmaceuticals plc", "longName": "Biodexa Pharmaceuticals Plc", "firstTradeDateEpochUtc": 1449498600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "77d68f67-48f8-35fb-8abb-8876c307ccfa", "messageBoardId": "finmb_278298574", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.51, "targetHighPrice": 8.0, "targetLowPrice": 8.0, "targetMeanPrice": 8.0, "targetMedianPrice": 8.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 1, "totalCash": 5971000, "totalCashPerShare": 0.003, "ebitda": -6458000, "totalDebt": 464000, "quickRatio": 1.199, "currentRatio": 1.262, "totalRevenue": 381000, "debtToEquity": 9.919, "revenuePerShare": 0.483, "returnOnAssets": -0.51379, "returnOnEquity": -1.80587, "freeCashflow": 348875, "operatingCashflow": -6826000, "revenueGrowth": -0.641, "grossMargins": 1.0, "operatingMargins": -28.433731, "financialCurrency": "GBP", "trailingPegRatio": null, "__fetch_time": "2024-05-01"}]